How Do Retatrutide, Tirzepatide, and Semaglutide Compare? A Chemical & Receptor-Selectivity Reference

WARNING: LABORATORY RESEARCH USE ONLY. This material is synthesized and distributed strictly for B2B development, laboratory research, and analytical studies. It is not a drug, dietary supplement, or cosmetic. Under no circumstances are these chemical compounds intended for human or veterinary diagnostic or therapeutic application. All research must be conducted by qualified laboratory personnel using appropriate safety controls.

Last reviewed: 2026-07-08 · Research use only.

Retatrutide, Tirzepatide, and Semaglutide are frequently grouped together, but from a chemical and pharmacological standpoint their defining difference is receptor selectivity — how many, and which, incretin-family receptors each peptide engages. This reference compares them strictly on chemistry: receptor targets, CAS identity, molecular parameters, and in vitro potency as reported in the primary literature. It makes no comparison of clinical efficacy, human outcomes, or suitability for any use — those are outside the scope of research-reagent characterization.

For the full chemical profile of our anchor compound, see the Retatrutide chemical reference.

1. At-a-Glance Chemical Comparison

On the disputed Retatrutide values: sources vary between C₂₂₁H₃₄₂N₄₆O₆₈ (≈4731.33 Da) and C₂₂₈H₃₅₀N₄₈O₆₆ (≈4894.58 Da), differing by salt form/linker accounting. See the Retatrutide reference for the full note.

2. Receptor Selectivity — the Core Chemical Distinction

The three peptides sit on a clear axis of increasing receptor breadth:

  Semaglutide      Tirzepatide          Retatrutide
   (mono)            (dual)               (triple)
      │                │  │                 │  │  │
   GLP-1R           GIP  GLP-1          GIP  GLP-1  GCGR

(Figure: receptor-engagement map. Replace with a labeled SVG carrying factual alt text on the published page — templates/_shared.md M8.)

• Semaglutide is a highly selective GLP-1 receptor agonist (a GLP-1 analogue sharing high sequence homology with native GLP-1).
• Tirzepatide adds GIP receptor engagement — a dual GIP/GLP-1 agonist built on a 39-amino-acid lipidated scaffold.
• Retatrutide adds a third target, the glucagon receptor (GCGR) — a triple GIP/GLP-1/glucagon agonist, also a 39-amino-acid lipidated scaffold.

This selectivity difference — mono → dual → triple — is the single most useful chemical distinction when selecting reference material for a receptor-signaling study.

3. In Vitro Potency, As Reported (read the caveat first)

Important methodological caveat: the EC50 values below come from different studies using different assay systems and cell lines. They characterize each molecule within its own report and are not directly head-to-head comparable; a smaller number here does not mean one compound is "stronger" or "better." Values are presented only to document each peptide's published in vitro receptor engagement.

*We do not assert a single cross-assay GLP-1R EC50 for Semaglutide here, because a value measured under a different protocol would invite an invalid head-to-head reading. Semaglutide's defining characteristic in this comparison is its mono-selectivity for GLP-1R.

4. Why These Distinctions Matter for Laboratory Research

Selecting reference material is an assay-design decision. A study modeling single-pathway GLP-1R signaling calls for a mono-agonist; work examining multi-receptor or GIP/glucagon-pathway cross-talk calls for a dual- or tri-agonist. Matching the peptide's receptor selectivity to the experimental question — and verifying its identity and purity by HPLC/MS — is what keeps cell-based results interpretable and reproducible.

5. Frequently Asked Questions

Q: What is the difference between Retatrutide, Tirzepatide, and Semaglutide? A: Chemically, they differ in receptor selectivity: Semaglutide is a GLP-1 mono-agonist, Tirzepatide is a GIP/GLP-1 dual agonist, and Retatrutide is a GIP/GLP-1/glucagon triple agonist.

Q: How many receptors does each peptide target? A: Semaglutide targets one (GLP-1R), Tirzepatide two (GIPR, GLP-1R), and Retatrutide three (GIPR, GLP-1R, GCGR).

Q: What are the CAS numbers for Retatrutide, Tirzepatide, and Semaglutide? A: Retatrutide is CAS 2381089-83-2, Tirzepatide is CAS 2023788-19-2, and Semaglutide is CAS 910463-68-2.

Q: Are Retatrutide and Tirzepatide the same size? A: Both are 39–amino-acid lipidated peptides, but they differ in sequence, molecular formula, and receptor selectivity (triple vs dual). Semaglutide is a smaller 31–amino-acid GLP-1 analogue.

Q: Can in vitro EC50 values be compared directly across these three peptides? A: No. Reported EC50 values come from different studies and assay systems; they document each molecule within its own report and should not be read as a direct head-to-head potency ranking.

6. Structured Data (JSON-LD)

{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Article",
      "headline": "How Do Retatrutide, Tirzepatide, and Semaglutide Compare? A Chemical & Receptor-Selectivity Reference",
      "author": { "@type": "Organization", "name": "Boss BioTech USA" },
      "publisher": { "@type": "Organization", "name": "Boss BioTech USA" },
      "datePublished": "2026-07-08",
      "dateModified": "2026-07-08"
    },
    { "@type": "ChemicalSubstance", "name": "Retatrutide", "alternateName": "LY3437943", "identifier": "CAS 2381089-83-2", "molecularFormula": "C221H342N46O68", "molecularWeight": "4731.33 g/mol", "description": "Triple GIP/GLP-1/glucagon receptor agonist peptide. Research use only." },
    { "@type": "ChemicalSubstance", "name": "Tirzepatide", "alternateName": "LY3298176", "identifier": "CAS 2023788-19-2", "molecularFormula": "C225H348N48O68", "molecularWeight": "4813.45 g/mol", "description": "Dual GIP/GLP-1 receptor agonist peptide. Research use only." },
    { "@type": "ChemicalSubstance", "name": "Semaglutide", "identifier": "CAS 910463-68-2", "molecularFormula": "C187H291N45O59", "molecularWeight": "4113.58 g/mol", "description": "Selective GLP-1 receptor agonist peptide (GLP-1 analogue). Research use only." },
    {
      "@type": "FAQPage",
      "mainEntity": [
        { "@type": "Question", "name": "What is the difference between Retatrutide, Tirzepatide, and Semaglutide?", "acceptedAnswer": { "@type": "Answer", "text": "Chemically they differ in receptor selectivity: Semaglutide is a GLP-1 mono-agonist, Tirzepatide is a GIP/GLP-1 dual agonist, and Retatrutide is a GIP/GLP-1/glucagon triple agonist." } },
        { "@type": "Question", "name": "How many receptors does each peptide target?", "acceptedAnswer": { "@type": "Answer", "text": "Semaglutide targets one (GLP-1R), Tirzepatide two (GIPR, GLP-1R), and Retatrutide three (GIPR, GLP-1R, GCGR)." } },
        { "@type": "Question", "name": "What are the CAS numbers for Retatrutide, Tirzepatide, and Semaglutide?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is CAS 2381089-83-2, Tirzepatide is CAS 2023788-19-2, and Semaglutide is CAS 910463-68-2." } },
        { "@type": "Question", "name": "Can in vitro EC50 values be compared directly across these three peptides?", "acceptedAnswer": { "@type": "Answer", "text": "No. Reported EC50 values come from different studies and assay systems and should not be read as a direct head-to-head potency ranking." } }
      ]
    }
  ]
}

7. Scholarly References

1. Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist… Cell Metabolism, 34(9), 1234–1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013
2. Coskun, T., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. https://doi.org/10.1016/j.molmet.2018.09.009
3. Lau, J., et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726
4. National Center for Biotechnology Information. PubChem Compound Summaries for Retatrutide, Tirzepatide (CID 156588324), and Semaglutide (CID 56843331). https://pubchem.ncbi.nlm.nih.gov

Clinical-development references above are cited strictly for the historical chemistry of each molecule, never as evidence of any benefit.

Related references: What is Retatrutide? (full chemical reference) · How to source high-purity Retatrutide (B2B verification guide)

Disclaimer: Boss BioTech USA distributes chemical compounds solely for laboratory research and analytical development. All products discussed above are not approved for human clinical use, diagnosis, prevention, treatment, or cure of any medical condition or disease. The purchaser assumes all risks associated with the handling, testing, and use of these materials.